You are here

Novartis

Novartis dances into JPM with $250M Calypso buyout, $185M RNAi alliance

Fierce Biotech

Mon, 01/8/24 - 11:33 am

Alphabet’s Isomorphic stacks two new deals with Lilly, Novartis worth nearly $3B ahead of JPM

Fierce Biotech

Sun, 01/7/24 - 04:19 pm

Why Novartis rebranded to tell patients, ‘We’re with you’

Medical Marketing and Media

Fri, 01/5/24 - 09:53 am

Novartis, Voyager launch another gene therapy mission with $100M upfront deal

Fierce Biotech

Tue, 01/2/24 - 10:05 am

Voyager Therapeutics

Huntington's disease

Roche, Novartis move Xolair closer to FDA finish line for food allergies

Fierce Pharma

Tue, 12/19/23 - 11:10 pm

Novartis unveils promising Fabhalta data for C3 glomerulopathy indication

Medical Marketing and Media

Tue, 12/12/23 - 09:56 am

clinical trials

C3 glomerulopathy

Novartis gears up for label expansion for Kisqali with Phase III results

Clinical Trials Arena

Mon, 12/11/23 - 11:18 am

clinical trials

early breast cancer

ASH: As Novartis enters PNH market, AstraZeneca shows longer term effect of its latest contender

Fierce Biotech

Mon, 12/11/23 - 10:07 am

Novartis hit with FDA letter detailing 'significant' Kymriah manufacturing shortfalls

Fierce Pharma

Thu, 12/7/23 - 10:08 am

drug manufacturing

Daiichi Sankyo unit claims $182m in Novartis patent dispute

Pharmaphorum

Wed, 12/6/23 - 10:31 am

Novartis receives FDA approval for Fabhalta to treat PNH in adults

Pharmaceutical Business Review

Wed, 12/6/23 - 10:25 am

paroxysmal nocturnal hemoglobinuria

Novartis sees brighter sales future as R&D revamp continues

BioPharma Dive

Tue, 11/28/23 - 11:36 pm

Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment

Fierce Biotech

Mon, 11/13/23 - 11:55 am

Novartis’ urticaria drug meets all endpoints in Phase III trials

Clinical Trials Arena

Fri, 11/10/23 - 10:05 am

chronic spontaneous urticaria

clinical trials

Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule

BioSpace

Tue, 11/7/23 - 10:05 am

Chong Kun Dang Pharmaceutical

small molecule drugs

FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

Yahoo Finance

Wed, 11/1/23 - 10:14 pm

Atrasentan data backs up Novartis’ $3.5bn Chinook deal

Pharmaphorum

Mon, 10/30/23 - 10:21 am

IgA nephropathy

Chinook Therapeutics

Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway

BioSpace

Sun, 10/29/23 - 08:53 pm

Bristol Myers Squibb

Novartis claims ex-staffer jumped to Takeda with 'thousands' of sensitive files

Fierce Pharma

Thu, 10/26/23 - 10:52 pm

Novartis Beats Earnings Estimate in Q3, Raises Full-Year Guidance

BioSpace

Tue, 10/24/23 - 07:46 pm

Pages